45 related articles for article (PubMed ID: 17870260)
1. Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function.
Hsiao SM; Chang SR
J Formos Med Assoc; 2024 Jun; 123(6):710-715. PubMed ID: 38092655
[TBL] [Abstract][Full Text] [Related]
2. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
4. Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women; a randomized controlled trial.
Saeideh Z; Raziyeh M; Soghrat F
J Reprod Infertil; 2010 Oct; 11(3):183-7. PubMed ID: 23926488
[TBL] [Abstract][Full Text] [Related]
5. Updated clinical recommendations for the use of tibolone in Asian women.
Huang KE; Baber R;
Climacteric; 2010 Aug; 13(4):317-27. PubMed ID: 20443720
[TBL] [Abstract][Full Text] [Related]
6. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
Biglia N; Maffei S; Lello S; Nappi RE
Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.
Wu MH; Pan HA; Wang ST; Hsu CC; Chang FM; Huang KE
Climacteric; 2001 Dec; 4(4):314-9. PubMed ID: 11770188
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene on sexual function in postmenopausal women.
Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
[TBL] [Abstract][Full Text] [Related]
9. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
10. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy.
Nappi RE; Ferdeghini F; Sampaolo P; Vaccaro P; De Leonardis C; Albani F; Salonia A; Polatti F
Maturitas; 2006 Oct; 55(3):288-95. PubMed ID: 16730929
[TBL] [Abstract][Full Text] [Related]
11. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
12. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
Nijland EA; Weijmar Schultz WC; Davis SR
Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
[TBL] [Abstract][Full Text] [Related]
13. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Kenemans P; Speroff L;
Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
